Barclays Hikes Eli Lilly Price Target to $1,400: Tirzepatide Momentum Steals the Show

Eli Lilly (NYSE:LLY | LLY Price Prediction) received another bullish call from Wall Street. Barclays analyst Emily Field raised her price target on Eli Lilly stock to $1,400 from $1,350 and reiterated an Overweight rating, citing tirzepatide momentum that “takes focus back to the big picture.” The firm also lifted its estimates following the company’s Q1 2026 report.

For long-term investors, the price target raised by Barclays signals that the multi-year GLP-1 thesis remains intact, even as quarter-to-quarter pricing noise persists. The call lands on the heels of a blowout earnings beat and raised full-year guidance.

The Analyst’s Case

Field’s “big picture” framing centers on tirzepatide, the active ingredient powering Mounjaro and Zepbound. Eli Lilly’s Q1 2026 revenue jumped 56% year over year (YoY) to $19.8 billion, beating consensus by 11%, while non-GAAP EPS of $8.55 topped the $6.79 estimate by 26%.

Mounjaro delivered $8.66 billion (up 125% YoY) on international expansion, and Zepbound contributed $4.16 billion in U.S. sales (up 80%). The franchise drove a 65% volume increase, offsetting a 13% drop in realized prices.

Company Snapshot

Eli Lilly is an Indianapolis-based pharmaceutical company whose products are sold in approximately 125 countries. CEO David A. Ricks raised full-year 2026 revenue guidance to $82 billion to $85 billion and non-GAAP EPS guidance to $35.50 to $37.

Beyond tirzepatide, the FDA approved Foundayo (orforglipron), the only GLP-1 pill that can be taken any time of day without food or water restrictions. Retatrutide, Eli Lilly’s triple-hormone agonist, also posted strong Phase 3 results in type 2 diabetes.

Why the Move Matters Now

Eli Lilly stock closed at $978.46 on May 4, leaving the new $1,400 target well above current levels. The shares carry a P/E ratio of 34x and a forward P/E ratio of 28x, with a consensus analyst target of $1,202.17.

The “big picture” thesis encompasses indication expansion into cardiovascular, sleep apnea, and MASH, oral GLP-1 scaling, and a pipeline strengthened by four announced acquisitions across cell therapy, sleep-wake disorders, in vivo CAR-T, and myelofibrosis. Rival Novo Nordisk (NYSE:NVO) shares are down roughly 33% over the past year, underscoring Eli Lilly’s widening competitive lead in GLP-1s.

What It Means for Your Portfolio

The bulls point to 56% revenue growth, raised guidance, and a deepening pipeline that could carry growth well past the GLP-1 patent cliff in the 2030s. The bear case includes payer pricing pressure, compounded GLP-1 competition, manufacturing capacity questions, and concentration risk in the tirzepatide franchise.

Eli Lilly stock has returned 409% over five years, though it’s down about 9% year to date (YTD). For prudent investors, Barclays’ refreshed target reinforces the long-term story, though moderate position sizing remains sensible given near-term volatility.

Keep an eye on Eli Lilly stock as Foundayo launch metrics, retatrutide obesity readouts, and the Medicare bridge program activation unfold through the second half of the year. These catalysts could shape sentiment around the Barclays thesis into 2027.